Sosei Heptares

News

Boehringer licenses Sosei schizophrenia drugs in €755m deal

Boehringer Ingelheim has taken an option on a family of compounds with potential as therapies for schizophrenia from Sosei Heptares, which it says could have broad activit

News

Sosei sees $3bn sales potential for GSK's IBD discard

Sosei Heptares has lost GSK as a partner for an inflammatory bowel disease (IBD) drug candidate GSK4381406, but says it will take the programme forward as it has significa

News

Chris Cargill, Sosei Heptares chief executive

Sosei snaps up Idorsia’s Japan, Korea units in $466m deal

Japan’s Sosei Group has completed a transition to a commercial-stage pharmaceutical company after buying rights to an already-marketed drug and a pipeline of experimental

News

close up of a prescription bottle with white tables falling out on top of a group of hundred dollar bills

Sosei nets $10m Pfizer milestone as diabetes/obesity drug st...

Sosei Heptares' longstanding alliance with Pfizer has advanced a first candidate into phase 2 testing: an oral GLP-1 agonist for diabetes and obesity that will try to take on established ri

Digital

Close up of lab assistant in uniform, with mask and rubber gloves holding test tube with blood sample while sitting on chair and typing on laptop. Selective focus on test tubes.

The future of AI drug discovery & development in immunology ...

Alphabet subsidiary and precision health company Verily recently announced a breakthrough in its AI drug discovery GPCR research collaboration with Sosei Heptares.

Oncology